Initial MS screening
. The set of cyclic GBB analogues used in initial substrate screening with BBOX. Only (1) was observed to be hydroxylated. The results imply that BBOX requires a quaternary ammonium centre for reactivity, since neither piperidine-4-carboxylic acid (5) nor N-methyl-piperidine-4-carboxylic acid (6) are substrates. Analogues with additional modifications in the piperidine ring (e.g. unsaturated analogue (7), or methylated analogue (8)) were not substrates. BBOX has an apparent requirement for a C-4 carboxylate, since (13) with a C-3 carboxylate was not hydroxylated. The 5-membered ring analogues were not hydroxylated.
Figure S2. LC-MS chromatogram of the reaction of BBOX with N,N-dimethylisonipecotic acid (1).
Spectra were recorded in mass range 120-300 Da (scan mode), single ion mode used in parallel to monitor masses: 158 (substrate, retention time = 9.68 min) and 174 (product, retention time = 8.02 min).
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Further NMR assignments of BBOX catalysed hydroxylation of (1) Figure S3 . Further NMR assignments of BBOX catalysed hydroxylation of (1). Multiplicity edited 1 H-13 C HSQC spectra of N,N -dimethyl isonipecotic acid (1) reaction with BBOX.
13
C NMR (from HSQC signals) (176 MHz, D 2 O)  ppm 63.7 (C 2 ), 63.4 (C 3 ), 61.8 (C 6 ), 54.7 (CH 3 ), 49.5 (C 4 ), 47.5 (CH 3 ), 22.52 (C 5 
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Crystallographical analyses Figure S4 . The crystal structure of human BBOX in complex with N,N-dimethylisonipecotic acid (1), NOG and Ni(II) is similar to that of the BBOX.GBB.NOG.Zn(II) complex [1] . (A) -View from the overall structure of the BBOX. (1) .NOG.Ni(II) complex dimer (PDB id: 4CWD). (B) -Overlay of a structure of the BBOX.GBB.NOG.Zn(II) complex monomer (PDB id: 3O2G, blue) and BBOX. (1) .NOG.Zn(II) complex monomer (PDB id: 4CWD, orange) reveal structural similarity. (C) -View from the active site of BBOX. (1) .NOG.Zn(II) complex with electron density maps (OMIT FoFc map contoured to 3σ).
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Conformational assignement of N,N-dimethyl isonipecotic acid
The 1 H NMR spectrum of (1) in D 2 O at room temperature displayed only one distinctive set of peaks, likely corresponding to a single conformer (Fig. S5 ). The position of H4, adjacent to the carboxylic group, was assigned as axial, based on its coupling constant analysis (J aa = 11.2 Hz, J ae = 4.6 Hz). The overall signal pattern was characteristic for a chair conformation (The slight phase distortions seen for the multiplets arises from the excitation sculpting water suppression scheme employed). 
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Preparation of N,N-ethylmethyl-piperidine-4-carboxylic acid (3)
N,N-Ethylmethyl-piperidine-4-carboxylic acid (3) was prepared from commercially available Nmethyl isonipecotic acid (6) and N-ethyl isonipecotic acid (15) via alkylation with requisite methyl/ethyl iodide at room temperature. In both cases, the resulting product was a mixture of two isomers (Scheme S1). Preferential 'axial' alkylation was observed under the tested reaction conditions.
Scheme S1. Synthesis of N,N-ethylmethyl-piperidine-4-carboxylic acid (3)
. Analogue (3) was prepared by alkylation of (6) or (15) by ethyl and methyl iodide (3 eq.), respectively. Reaction was conducted in methanol in the presence of K 2 CO 3 (3 eq.) in methanol at room temperature.
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Assignment of N,N-ethylmethyl-piperidine-4-carboxylic acid isomers Figure S7 . 1 
S8
The methyl group position was assigned by nOe studies (Fig. S8 ). The H4 proton (i.e. adjacent to the carboxylate) was assigned to be axial in both isomers of (3) by the coupling constants pattern in the 1 H NMR spectra (isomer A: J aa = 10.2 Hz, J ae = 5.1 Hz; isomer B: J aa = 11.5 Hz, J ae = 4.8 Hz). 
Assignments of product of BBOX catalysed hydroxylation of N,N-ethylmethylpiperidine-4-carboxylic acid (3)
Mixtures of isomers (3a) and (3b) (mixture 1: (3a):(3b) = 2:1, mixture 2: (3a):(3b) = 1:3) were subjected to BBOX catalysed oxidation. MS based assay indicated the formation of new species with a mass shift of +16, corresponding to a single hydroxylation (Fig. S9) . In case of both Mixture 1 and 2 a formation of new peaks in the 1 H NMR spectra was observed. In both cases, the presence of two new peaks, characteristic for axial protons adjacent to hydroxyl and carboxylate moiety was observed (4.17 and 2.32 ppm, respectively) ( Fig. S10 and S11 ). In case of mixture 1, where isomer (3a) was the major component only one set of new peaks was observed, indicating that (3a) is the preferred substrate. Interestingly, for mixture 2, where isomer (3b) was the major component, the presence of second set of product peaks was detected; the major product was the same as that observed with Mixture 1 (Fig. S10 and S11 ). The result suggest that (3b) is hydroxylated by BBOX, but is a less preferred substrate than (3a) (even though (3b) was in excess in Mixture 2, the major product arises from hydroxylation of the minor component (3a)). Due to the low level of (3b) hydroxylation and signal overlap the stereochemistry of minor product has not been assigned with confidence. H NMR spectra of cyclic analogue reaction mixtures. (a) H 3 peak of BBOX catalysed oxidation of (1). H 3 was assigned to be in axial position (J aa = 10.8 Hz × 2, J ae = 4.7 Hz). (b) When a mixture of (3a):(3b) = 2:1 was subjected to BBOX, H 3 was also assigned to be axial (J aa = 10.4 Hz × 2, J ae = 4.4 Hz). Only one hydroxylation product was observed. (c) When a mixture of (3a):(3b) = 1:3 was subjected to BBOX, two peaks corresponding to H 3 were observed, both assigned as axial protons (major: J aa = 10.5 Hz × 2, J ae = 4.4 Hz, minor: J aa = 11.1 Hz × 2, J ae = 5.4 Hz). The major product is same as that product obtained for the mixture in (b) and corresponds to the hydroxylation product of (3a) to give (4a). The minor product likely corresponds to hydroxylation of (3b) to give (4b), which was the major component of substrate mixture used in (c). 
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Kinetic analyses [2] . **yield is given as a percentage conversion of substrate into hydroxylated product (as calculated 
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Experimental Enzyme production
Recombinant human BBOX was produced and purified as described [1] .
MS methods
Initial MS screening
Initial screens for BBOX substrates were performed on Waters LCT Premier Instrument, employing
Electron impact Chemical Ionisation, fitted with time of flight (ToF) analyser. Samples were measured using direct injection (no column attached) and analysed for the presence of a +16 peak. 
LC-MS method
Chromatographic separation of the GBB analogues was performed using mixed mode chromatography. Chromatographic separation was performed using an Aquity UPLC system 
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NMR
NMR assays were performed using a Bruker AVIII 700 instrument equipped with an inverse TCI cryoprobe using 3 mm MATCH tubes. Pulses were calibrated using single-pulse nutation method (Bruker pulsecal routine). Water suppression was achieved using the excitation sculpting method.
Hydroxylation product assignment
Hydroxylation reactions were performed using the following conditions: 0. Protein (20 mg/ml) was in TRIS buffer (50 mM pH 7.5) containing 200 mM NaCl and was supplemented with 5 mM N,N-dimethylisonipecotic acid (1) and 10 mM NOG (100 mM stock solutions in TRIS 50 mM, pH adjusted to 7.0) prior to crystallization. Crystals formed overnight.
Crystals were harvested in nylon loops and flash cooled in liquid nitrogen using 25% glycerol in mother liquor as a cryoprotectant. Data were collected on a single crystal in-house using a Rigaku FRE+ SuperBright X-ray diffractometer equipped with Osmic HF optics and a Saturn944+ CCD detector. Data were integrated and scaled using HKL3000 [3] . The structure was solved by molecular replacement using PHASER [4] (search model PDB ID: 3O2G). Iterative cycles of model building in COOT [5] and refinement using PHENIX [6] proceeded until the converging R cryst and R free no longer decreased. 
Structural
General procedure for the synthesis of cyclic GBB analogues
The appropriate amino acid (1 equiv.) was dissolved in methanol (5 mL 
4-Carboxy-1,1-dimethylpiperidin-1-ium (1)
The trifluoroacetic acid (TFA) salt of desired product (11 mg, 0.04 mmol, 10%) was obtained starting from isonipecotic acid (50 mg, 0.39 mmol) by following the general procedure. 
4-Carboxy-1-ethyl-1-methylpiperidin-1-ium (2)
The trifluoroacetic acid (TFA) salt of desired product (9 mg, 0.03 mmol, 8%) was obtained starting from N-methylisonipecotic acid (50 mg, 0.39 mmol) or N-ethylisonipecotic acid (50 mg, 0.38 mmol)
by following the general procedure. The compound was obtained as a mixture of conformers. 
4-Carboxy-N,N,N-trimethylcyclohexan-1-aminium (14)
The trifluoroacetic acid (TFA) salt of desired product (11 mg, 0.04 mmol, 11%) was obtained starting from isonipecotic acid (50 mg, 0.35 mmol) by following the general procedure. 
